Laboratory of Clinical Microbiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Microbiol Spectr. 2023 Jun 15;11(3):e0141422. doi: 10.1128/spectrum.01414-22. Epub 2023 May 8.
Tuberculosis remains a major global public concern as a leading cause of health care-associated infections. The detection of Mycobacterium tuberculosis (MTB) is challenging due to the paucibacillary nature of the pathogen. For suspected pulmonary and extrapulmonary tuberculosis patients, if sputum, bronchoalveolar lavage fluid (BALF), related samples are negative for MTB, or suspected tumors, biopsy tissues may provide a better diagnostic yield. This study was aimed at comparing the performances of three methods in identifying MTB in biopsy tissues, including the Bactec mycobacterial growth indicator tube 960 (MGIT 960) system, the GeneXpert MTB/RIF assay (GeneXpert), and the Bactec Myco/F lytic culture (Myco/F) system. Biopsy samples from 3,209 nonduplicated patients were retrospectively enrolled between January 2018 and September 2021, of which 180 (5.6%) were positive for MTB by at least one method. GeneXpert revealed the highest recovery rate (134/162, 82.7%), followed by MGIT 960 (99/135, 73.3%) and Myco/F (26/143, 18.1%), and the composite positive rate for GeneXpert and MGIT 960 was 96.6% (173/179). Pairwise comparisons were conducted after completion of both tests, and the results showed that Myco/F had significantly lower detection rates than GeneXpert and MGIT 960 (16.4% versus 82.8%, 0.001; 14.3% versus 71.4%, 0.001). In summary, GeneXpert was the most sensitive and recommended method for MTB detection in biopsy tissues, and the combination of GeneXpert and MGIT 960 could improve the overall diagnostic yield. Mycobacterium tuberculosis (MTB) poses a severe threat to public health worldwide. The diagnosis of tuberculosis is challenging due to the low load of the microorganism in samples. Biopsy tissues are sometimes collected via invasive procedures with limited size, and additional samples are often inaccessible. The GeneXpert MTB/RIF assay, Bactec MGIT 960 system, and Bactec Myco/F lytic system have been used in detecting MTB in our laboratory. Here, we evaluated the performances of these three methods in 3,209 biopsy tissues samples to establish a more effective protocol based on clinical requirements. Attempts for a locally optimized protocol should be always made.
结核病仍然是一个主要的全球公共卫生问题,是导致医疗保健相关感染的主要原因。由于病原体的菌量少,分枝杆菌(MTB)的检测具有挑战性。对于疑似肺和肺外结核病患者,如果痰、支气管肺泡灌洗液(BALF)等相关样本 MTB 检测结果为阴性,或疑似肿瘤,活检组织可能会提供更好的诊断效果。本研究旨在比较三种方法在识别活检组织中的 MTB 方面的性能,包括 Bactec 分枝杆菌生长指示管 960(MGIT 960)系统、GeneXpert MTB/RIF 检测(GeneXpert)和 Bactec Myco/F 裂解培养系统。2018 年 1 月至 2021 年 9 月,回顾性纳入 3209 例非重复患者的活检样本,其中至少一种方法检测 MTB 阳性的有 180 例(5.6%)。GeneXpert 显示出最高的回收率(134/162,82.7%),其次是 MGIT 960(99/135,73.3%)和 Myco/F(26/143,18.1%),GeneXpert 和 MGIT 960 的复合阳性率为 96.6%(173/179)。两种检测方法均完成后进行两两比较,结果显示 Myco/F 的检测率明显低于 GeneXpert 和 MGIT 960(16.4%对 82.8%,0.001;14.3%对 71.4%,0.001)。综上所述,GeneXpert 是检测活检组织中 MTB 最敏感的推荐方法,GeneXpert 和 MGIT 960 的联合应用可以提高整体诊断效果。分枝杆菌(MTB)对全球公共卫生构成严重威胁。由于样本中微生物的载量低,结核病的诊断具有挑战性。活检组织有时通过有限大小的侵入性程序采集,并且通常无法获得其他样本。GeneXpert MTB/RIF 检测、Bactec MGIT 960 系统和 Bactec Myco/F 裂解系统已在我们的实验室中用于检测 MTB。在这里,我们评估了这三种方法在 3209 份活检组织样本中的性能,以根据临床需求建立更有效的方案。应该始终尝试制定本地优化方案。